Brain Tumor FDA’s breakthrough designation helps the researchers expedite the development and review of the drug for which its success shows a substantial improvement over available therapy for brain cancer. In the case of recurrent glioblastoma, the extremely aggressive tumors grow and spread rapidly, leaving patients with less than a year of survival even with the existing aggressive treatment options. Although the designation does not indicate approval for the drug, Duke’s brain tumor center director Dr. Darell Bigner said, “Ultimately, we hope the therapy will one day obtain FDA approval.”
This Injection Tricks the Immune System
Brain Tumor The treatment uses a modified this Injection to stimulate the person’s immune system to fight off the cancer. According to Duke molecular biologist Matthias Gromeier, who engineered the this Injection cancerous tumors fight off the immune system by developing a “shroud” around the cancer that the immune system cannot penetrate.
However, the researchers found that when the modified this Injection is introduced into the cancer cells, the body perceives a polio infection and, ultimately, is tricked into attacking the cancer cells. The virus not only breaks down the cancer cells, but enables the immune system to attack, giving the cancer a doubly lethal blow.
Brain Tumor The researchers were shocked by the successes they saw in the Phase I trial, which are typically used to allow the researchers to find the appropriate dosing. However, Dr. Friedman, Deputy Director, The Preston Robert Tisch Brain Tumor Center at Duke University, said any other results are “cake.” The researchers got the “biggest cake we’ve seen in a long, long time,” according to Dr. Friedman, when the first infusions in patients led to an attack on the tumors leaving them virtually cancer free.